Cytokinetics Claims Myqorzo Launch Momentum and nHCM Filing Plans, but Valuation and Execution Risks Persist
Read source articleWhat happened
Cytokinetics executives announced that the launch of Myqorzo in obstructive HCM is gaining momentum and that the company is preparing a U.S. regulatory filing for use in non-obstructive HCM. This announcement comes after the FDA approved Myqorzo in December 2025, with commercial availability starting in January 2026, and the company had previously guided for ACACIA Phase 3 nHCM data in Q2 2026, implying that the filing is based on positive trial results. However, the DeepValue master report, which reflects a 'POTENTIAL SELL' rating with a bear case probability of 30% and an attractive entry around $50, highlighted that even with nHCM success, the stock's valuation at $63 already prices in a rapid, high-share launch against Bristol Myers' entrenched Camzyos. The report also stressed that management's 'momentum' claim must be substantiated by actual prescription, payer coverage, and net sales data, as prior disclosures showed no commercial revenue through Q3 2025 and the company has a history of promotional language. Therefore, while the planned nHCM filing reduces a key downside risk, the core investment thesis remains unchanged: the risk-reward at current levels still skews to the downside unless launch execution exceeds high expectations.
Implication
If the nHCM filing is based on robust ACACIA data, it validates the second indication and may support a higher probability for the bull case, potentially lifting the stock toward the $85 scenario. However, Myqorzo still must dislodge an entrenched Camzyos that had over 12,500 U.S. patients on therapy by mid-2025 and a simplified label, while Cytokinetics carries negative equity, high cash burn, and royalty burdens. The stock's crowded bullish positioning and recent insider selling add risk of sharp pullbacks on any launch disappointment. Investors who hold the stock should consider trimming into strength above $80, as the DeepValue report suggests, and new longs should wait for either a pullback toward $50 or clear evidence of above-consensus Myqorzo sales in 2026. Overall, a cautious stance is warranted until management provides verifiable launch metrics.
Thesis delta
The new information that management is planning an FDA filing for nHCM likely confirms that ACACIA results were positive, which reduces the bear case probability tied to that trial. However, without concrete launch metrics, the shift in scenario probabilities is modest: the base case remains most likely, and the stock's valuation continues to embed ambitious ramp assumptions. We therefore maintain the 'POTENTIAL SELL' stance with a trim above $80 and an attractive entry near $50, while monitoring launch data closely.
Confidence
Medium